Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.

Publication

Citation
Crosignani S, Page P, Missotten M, Colovray V, Cleva C, Arrighi JF, Atherall J, Macritchie J, Martin T, Humbert Y, Gaudet M, Pupowicz D, Maio M, Pittet PA, Golzio L, Giachetti C, Rocha C, Bernardinelli G, Filinchuk Y, Scheer A, Schwarz MK, Chollet A.: Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases. J Med Chem, Volume 51 (7), 2008
Authors
Arrighi JF, Atherall J, Bernardinelli G, Chollet A., Cleva C, Colovray V, Crosignani S, Filinchuk Y, Gaudet M, Giachetti C, Golzio L, Humbert Y, Macritchie J, Maio M, Martin T, Missotten M, Page P, Pittet PA, Pupowicz D, Rocha C, Scheer A, Schwarz MK
Journal
J Med Chem
Year
2008
PubMed
18318469
Machine-readable
REST APIRDF
Palacky University Olomouc

Palacky University Olomouc

Faculty of Science

Department of Physical Chemistry

tř. 17. listopadu 1192/12

771 46 Olomouc

Czech Republic

How to cite?

Juračka J., Šrejber M., Melíková M., Bazgier V., Berka K.: MolMeDB: Molecules on Membranes Database. Database, Volume 2019, 2019, baz078, https://doi.org/10.1093/database/baz078

Follow us

FacebookGithub

Financial Support

  • MolMeDB interoperability with UniProt and SwissLipids – MEYS Czech-Swiss project ELIXIR-IMPACT 8K0208 (2026–2028)
ELIXIRGAČRUP Olomouc
Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases. | MolMeDB